5 Top NASDAQ Biotech Stocks: Neovasc Wins the Week
Neovasc, Arbutus Biopharma, Aralez Pharmaceuticals, CASI Pharmaceuticals and Nabriva Therapeutics top the NASDAQ biotech stock list.
Your trusted source for investing success
Your trusted source for investing success
Neovasc, Arbutus Biopharma, Aralez Pharmaceuticals, CASI Pharmaceuticals and Nabriva Therapeutics top the NASDAQ biotech stock list.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
The Investing News reported took a closer look at some of the big cannabis news of the week and published an interview with the president of Cannabis Wheaton.
VIVUS announced it entered into a settlement agreement with Dr. Reddy’s Laboratories related to the patent litigation of Qsymia capsules CIV.
Depomed a specialty pharmaceutical focused on pain relief therapies was hit on Monday by a class action lawsuit announcement from law firm Levi & Korsinsky.
Insys Therapeutics has settled a suit with the state of Illinois, in which the company will have to pay $4.5 million due to their marketing and selling tactics of their fentanyl-based treatment Subsys.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
This past trading in the cannabis marketplace saw another major dip to the Marijuana Life Sciences Index, the first medical marijuana study funded by a US medical government research group.
From Canadian LPs banding together asking for tougher promotional regulations to the acquisition of ABcann by Cannabis Wheaton and a variety of market news INN provides a roundup of the week in cannabis.
By Shelly Kumar
Valens GroWorks (CSE:VGW)(CSE:VGW.CN) (the “Company” or “Valens“) is pleased to announce that Mr. Saul Katz has joined the Company as its President.
Mr. Katz brings to Valens 35 years of entrepreneurship, senior management experience and scientific expertise in functional food product development and commercialization. Over his career he established research collaborations with leading
By Melissa Shaw
The company will supply a planned 15GWh lithium-ion battery gigafactory in New York with anode materials and technologies.
Beleave Inc. (“Beleave”) (CSE: BE) (CSE: BE.CN) (CNSX: BE) is pleased to announce that it will begin a clinical research program with Dr. Mohit Bhandari, to investigate the therapeutic use of cannabinoids for management of pain in musculoskeletal disorders. In North America, Europe, and Australia, chronic non-cancer pain is a
By Pia Rivera
An update on the major issues affecting technology companies under the Trump presidency.
By Emma Harwood
Wi2Wi Corporation (TSXV:YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors.
As quoted
Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to provide a development update on its FAIMS Beta 2.0 (field asymmetric waveform ion mobility spectrometry) based marijuana breathalyzer for the detection of ∆9-tetrahydrocannabinol (“THC”) in human
The company bought the remaining stake in the Mutanda mine and increased its interest in Katanga mine.
2016 saw countless pharmaceutical companies taken to task for price gouging. Close to the end of the year, a related topic made headlines: price collusion, this time among generic drug manufacturers.
